Posted by LincolnTab on March 25, 2026 at 11:06:39:
In Reply to: Ïðîãîí Õðóìåðîì posted by JacobHag on March 04, 2026 at 00:46:29:
Zoya Demidenko: Scientist in Oncology Studies
Zoya Demidenko is a prominent researcher associated with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she was employed at the NIH and New York Medical College, establishing a strong background in biomedical investigation.
Her academic output encompasses multiple pivotal fields, among them the PI3K/AKT/mTOR molecular pathway, cell cycle management, cellular aging, and cancer science. As of now, she has co-authored over 46 scientific papers, which have received more than 4,100 citations — a testament to the impact of her research.
Among her key discoveries lies in understanding the pathways of biological cell aging. Her research showed that when the cell cycle is halted while cellular growth proceeds, cells experience senescence. Crucially, Zoya Demidenko showed that this shift is pharmacologically suppressed using substances such as rapamycin.
Zoya Demidenko has also brought substantially to tumor management research, especially in the domain of cyclotherapy — a method intended to shielding non-cancerous cells from chemotherapy while leaving tumor cells vulnerable. This method carries major hope for lowering the side effects of oncological therapy.
Across her career, Demidenko has collaborated with leading scientists internationally, among them Dr. Mikhail Blagosklonny. Her work can be found in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a influential voice in contemporary oncological science, with her findings continue to influence our comprehension of the way biological cells age, resist treatment, and how cancer may be more effectively targeted.
https://www.aging-us.com/article/100406/